west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "药物相互作用" 4 results
  • Analysis of Clinical Unreasonable Use of Drug

    为了促进药物的合理应用,本文从药物相互作用、配伍禁忌、药物选用、用法用量等方面对临床常见的不合理用药医嘱进行了探讨,指出用药不当的原因和可能的后果,帮助临床有效地防范不合理用药的发生,有利于针对性地提高临床合理用药水平。

    Release date:2016-09-08 10:14 Export PDF Favorites Scan
  • 抗菌药物与细胞色素P450的相关研究

    抗菌药物广泛地应用于临床各个科室,常常与多种药物联合应用而产生药物相互作用。肝微粒体细胞色素P450是药物代谢最重要的酶系之一,药物作用影响其活性是发生药物相互作用的重要分子机制。了解抗菌药物与细胞色素P450的相关关系,有助于明确药物相互作用的分子基础,有助于指导临床合理联合用药,保障临床治疗更加安全有效。现就抗菌药物与细胞色素P450的相关研究作一综述。

    Release date:2016-09-08 09:16 Export PDF Favorites Scan
  • 国内外结核病诊疗指南中关于抗结核药物相互作用管理的分析

    我国是世界结核病大国,患病人数位居世界第2位,仅次于印度。结核病严重危害人民健康,是我国重点防控的重大疾病之一。其为慢性传染病,需要长期多药联合治疗,而在长期治疗过程中患者往往因合并疾病需要同时使用其他药物,从而增加了药物相互作用的风险,导致药物不良反应增加或疗效降低。常见的合并疾病包括高血压、冠状动脉粥样硬化性心脏病、糖尿病、真菌性疾病和艾滋病等,需要β肾上腺素能受体阻滞剂、血管紧张素转换酶抑制剂、血管紧张素受体拮抗剂、钙通道阻滞剂、口服降糖药、三唑类抗真菌药和抗逆转录病毒药等治疗,这些药物都与抗结核药存在相互作用。如何管理药物相互作用,是临床医师和药师共同关注的问题。通过检索国内外中英文结核病诊疗指南,总结指南中关于抗结核药物相互作用的管理办法,以期为临床医师和药师提供权威的参考意见。现就指南中药物相互作用管理的推荐意见进行综述。

    Release date: Export PDF Favorites Scan
  • Combination Therapy of Atorvastatin and JiangZhi Decoction for Primary Hyperlipidemia (Tan Zhuo Zu E Zheng): A Stratified Randomized Controlled Trial

    ObjectTo observe the clinical efficacy and safety of the combination therapy of atorvastatin and JiangZhi Decoction (ZJD) for primary hyperlipidemia (Tan Zhuo Zu E Zheng) and to analyze the interactions of drugs in hypolipidemic effect. MethodsA 2*2 factorial design, single-blind, stratified randomized controlled trial according to the level of lipid was conducted. Primary hyperlipidemia (Tan Zhuo Zu E Zheng) patients met the inclusion criteria were divided into 5 groups:ATV 10 mg group (group A), ATV 20 mg group (group B), ATV 10 mg+JZD group (group C), ATV 20 mg+JZD group (group D), JZD group (group E). After two weeks treatment, the efficacy and safety among the 5 groups were compared. ResultsA total of 92 patients were included, of which, 20 were in group A, 25 in group B, 21 in group C, 17 in group D, and 9 in group E. The results showed that:(1) There was no significant difference between group C and group B in the reduction of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) (PTC=0.226, PLDL-C=0.818). (2) The results of 2*2 factorial analysis showed that, there was no significant interaction between TCM factor and western medicine factor (PTC=0.605, PLDL-C=0.843). (3) There were no significant differences in safety outcomes among 5 groups (all P values >0.05). ConclusionATV 10 mg+JZD and ATV 20 mg have a similar efficacy in reducing TC and LDL-C. There is no obvious interaction between JZD and ATV in hypolipidemic effect, and the combination therapy of ATV and JZD is safe.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content